Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.

Drugs of today (Barcelona, Spain : 1998) - 1 Nov 2016

Eagles J R, Jimeno A

Abstract excerpt

Historically, metastatic melanoma has had extremely poor survival outcomes. The outlook, however, is rapidly changing as new molecularly targeted therapies have vastly improved patient outcomes. One such therapy is the potent mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor cobimetinib. Recently, cobimetinib was approved for the treatment of metastatic or unresectable melanoma with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azetidines
Share to Clinical Trials as Topic
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase 1

Share to MAP Kinase Kinase 2

Share to Melanoma

Share to Piperidines

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 28112278
DOI: 10.1358/dot.2016.52.11.2542234

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.PMID 28112278Read ↗

The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.Semantic proximity Read ↗

Cobimetinib and vemurafenib for the treatment of melanoma.Semantic proximity Read ↗

Cobimetinib.Semantic proximity Read ↗

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.Semantic proximity Read ↗

Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.Semantic proximity Read ↗

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.Semantic proximity Read ↗

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.Semantic proximity Read ↗

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.Semantic proximity Read ↗

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)Semantic proximity Read ↗

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.Semantic proximity Read ↗

Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.Semantic proximity Read ↗

A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.